Fig 1.
NH demographics, breast clinico-pathological characteristics, and treatment compared between patients with or without tumor recurrence.
(A) The numbers and percentages of patients displaying demographic and (B) breast clinico-pathological characteristics were compared for patients with (n = 225) and without recurrence (n = 6009). (C) The numbers and percentages of tumor recurrences for patients whose disease either recurred or did not recur, were compared in patients who underwent each form of conventional breast cancer treatment. Significant differences in all clinico-pathologic characteristics were observed between patients with or without tumor recurrence (p<0.0001), with the exception of nodal status (p = 0.121). Significant differences in clinico-pathological features were also observed between recurrence and non-recurrence patients receiving each form of treatment (p<0.0001), except for radiation therapy (p = 0.065). A chi-square statistical analysis was used to generate p-values in order to determine significant differences in the proportion of patients exhibiting or not exhibiting recurrence in each category. For example, regarding grade, a p value of 0.02 represents a significant difference for the distribution of recurrence and non-recurrence patients across all grades. Please refer to Supplementary Table 1 for details.
Fig 2.
NH demographics, breast, clinico-pathological and treatment compared between AA and EA with tumor recurrence.
(A) The demographic and (B) clinico-pathological characteristics of AA (n = 49) and EA (n = 166) patients with recurrence in the NH cohort were compared. (C) Treatment administration was also compared between AA and EA recurrent breast cancer patients. A chi-square analysis was used to determine statistically significant differences in the proportion of AA and EA patients exhibiting each characteristic and undergoing each form of treatment. No statistically significant differences were observed. Please refer to Supplementary Table 2 for details.
Table 1.
Broad-spectrum recurrence patterns among racially distinct populations.
Table 2.
Recurrence rates and patterns after receiving any form of treatment among racially distinct populations.
Table 3.
Overall recurrence rates among racially distinct staged breast cancer patients.
Fig 3.
AA exhibit lower survival duration than EA among recurrent breast cancer patients.
(A) Survival time from first recurrence episode until death was compared between AA and EA breast cancer patients. Log-rank analysis was conducted to determine statistical differences between the racial groups. AA exhibited a non-significant lower survival time than EA (p = 0.231). (B) The mean time (days) until death was compared between AA and EA breast cancer patients displaying distant recurrence. AA died notably sooner than EA patients (p = 0.015). A t-test was performed to determine significant differences between the racial groups.